Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00077116
Status:
COMPLETED
Last Update Posted:
2012-07-16
First Post:
2004-02-10
Brief Title:
Idarubicin Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Organization:
European Organisation for Research and Treatment of Cancer - EORTC
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Myelodysplastic Syndromes |
| Leukemia |
Keywords:
| Name | View |
|---|---|
| childhood myelodysplastic syndromes | View |
| untreated adult acute myeloid leukemia | View |
| refractory anemia with excess blasts | View |
| refractory anemia with excess blasts in transformation | View |
| chronic myelomonocytic leukemia | View |
| de novo myelodysplastic syndromes | View |
| secondary myelodysplastic syndromes | View |
| adult acute myeloid leukemia with t821q22q22 | View |
| adult acute myeloid leukemia with t1616p13q22 | View |
| adult acute myeloid leukemia with inv16p13q22 | View |
| adult acute myeloid leukemia with 11q23 MLL abnormalities | View |
| adult acute myeloid leukemia with t1517q22q12 | View |